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Tumor necrosis factor is a potent agent possessing diverse biologi- 
cal functions. We investigated the effects of intravenous administration 
of human recombinant tumor necrosis factor (TNF) on immune cell popula- 
tions in CBA/J mice. The animals developed a significant lymphopenia and 
neutrophilia both reaching a maximum at 4 hours post-injection with a 
trend towards resolution to normal values by 6 hours. The lymphopenia 
was both relative and absolute. Similarly, the neutrophilia was both 
relative and absolute and was due to the presence of both immature and 
mature neutrophils. As the neutrophilia and lymphopenia occurred concom- 
itantly, there was no difference at any time point in the total number of 
peripheral blood white cells. Extensive controls were done to rule out 
LPS contamination in the TNF preparation. These data demonstrate the 
potent effects of intravenous administration of human recombinant tumor 
necrosis factor on peripheral blood constituents. © 1986 Academic Press, Inc. 
Tumor necrosis factor (TNF) is a macrophage derived peptide that has 
a number of functions directed against diverse cell types (I). Several 
in vitro studies have demonstrated TNF's ability to modulate the prolif- 
eration of mammalian cell lines (2), increase endothelial adhesiveness 
(3) and enhance phagocytic cell activity (4). In vivo studies have 
generally focused on the oncolytic activity of the TNF on solid tumors 
and characterization of physiological properties in various species has 
been limited. 
Recent work by Beutler (5) has suggested that TNF represents the 
final mediator molecule that accounts for the changes observed when 
lipopolysaccharide (LPS) is given systemically. While previous investi- 
gations have demonstrated that the intravenous administration of LPS 
Abbreviations: LPS-lipopolysaccharide, PMN-polymorphonuclear neutrophils, 
TNF-tumor necrosis factor 
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causes marked changes in peripheral blood leukocyte populations when 
given to human (6-8) or calves (9), we now report similar effects induced 
by the systemic administration of human recombinant TNF. Kinetic studies 
showed alterations in peripheral blood leukocyte populations that began 
within 15 minutes and persisted to 6 hours. Numerous control studies 
showed that these changes were not due to lipopolysaccharide 
contamination. 
Materials and Methods 
Animals: Female CBA/J mice (Jackson Labs, Bar Harbor, ME were used 
throughout this study. The mice were maintained under standard care and 
given food and water ad libitual. 
In vivo effects of TNF: Recombinant human TNF (A gift from Dr. Leo 
Ling, Cetus, Corp., Emeryville, CA) was administered to mice via a single 
200 ~i bolus tail vein injection. Prior to use, the TNF stock solution 
was diluted with pyrogen-free normal saline 1 to 20 such that 1Ng/mouse 
was administered in 200 ~i (I ~g TNF equals 104 units of activity). 
Control mice received 200 ~i of normal saline and were sacrificed 2 hours 
later. 
Kinetics study: At specific time points post-administration, the 
animals were sacrificed and blood was anticoagulated with 0.I ml of 50 mM 
EDTA (Sigma, St. Louis, MO), I0 mM phosphate-buffered saline pH 7.4. The 
volume was measured and a white count performed with a unopette (Becton- 
Dickinson, Rutherford, NJ). A smear was prepared, stained with Wright- 
Geimsa and a 100-cell differential was done with the observer blinded as 
to the nature of the specimen. Immature PMNs were defined as those cells 
with plump, ring nuclei (i0). Time 0 represents values from normal mice. 
Controls: As determined by the limulus assay the LPS contamination 
was less than 38 ng/mg of protein, an amount corresponding to a less than 
1.5 ng LPS/mouse. LPS (Sigma Chemical Co. St. Louis, MO) was injected in 
a 200 ~I bolus intravenously at 1.0 ng/mouse and the blood was collected 
2 hours later. A second control consisted of inactivating LPS activity 
by mixing the diluted TNF preparation with polymyxin B (Sigma Chemical 
Co., St. Louis, MO) for 30 minutes at 37°C (11). The third control 
consisted of heat inactivation of the TNF preparation. Controls were 
compared to treated mice by Students t-test for all studies. 
Results 
Human recombinant TNF had a dramatic effect on the peripheral blood 
leukocytes. In a normal CBA/J mouse the predominant peripheral blood 
leukocyte is the lymphocyte, representing 77 ± 10% of cells, while 
neutrophils comprise 21 ± 10% (mean ± SD). Injection of normal saline 
causes some alterations compared to normal mice, but not as dramatic as 
with the TNF challenge. Two hours post-injection of 1 ~g TNF, lymphocyte 
numbers fell by more than 64%. In contrast, there was a 250% increase in 
the percentage of peripheral blood neutrophils. These alterations in the 
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Table 1 
Experiments controlling for lipopolysaccharide (LPS) contamination of the TNF 
preparation 
Material 
Injected % Cells Cells/ml (xl04) 
Lymphs PMNs Total Lymphs PMNs 
Nothing 77±I0 21±10 374±154 294±135 75±37 
Normal Saline 58±9 41±9 346±10 ]48±55 I15±65 
TNF l~g 28±6" 70±6* 300±6g 77±29" 193±80" 
TNF l~g, Heated 58±12 41±12 427±127 241±3 185±97 
LPS Ing 55±9 45±9 355±157 200±59 180±97 
TNF l~g + 43±1" 57±1" 310±60 134±27 176±34 
Polymyxin B 
The material was injected intravenously and the blood collected 2 
hours later. The TNF preparation caused a lymphopenia and neutrophilia which was 
both relative and absolute. Heating the TNF abolished this activity. LPS did not 
affect the peripheral blood leukocyte populations. Mixing the TNF with polymyxin 
B, to inactivate any possible LSP contamination, did not eliminate the prepara- 
tion's ability to induce alter leukocyte populations. Each point is the mean ± SD 
for 3 to 8 mice. * = p<.05. 
circulating white blood cell populations were not only relative, but were 
also absolute, as indicated by the changes in the total numbers of 
lymphocytes and neutrophils. The total white count did not vary signifi- 
cantly since the increase in PMNs offset the decrease in lymphocytes. 
These results are summarized in Table I. 
Lipopolysaccharide (LPS) contamination can induce profound changes 
in the peripheral blood values (6-8), therefore, it was important to rule 
out any effects due to LPS contamination. Three separate control experi- 
ments were conducted to document that the observed effects were due to 
the TNF preparation and not LPS contamination. First, LPS was not 
detectable in the TNF sample by the limulus assay, and an intravenous 
challenge of LPS at the levels potentially found in the TNF preparation 
did not affect our system. Second, heating the TNF preparation, which 
destroys TNF activity but not LPS, eliminated the observed effects of the 
TNF. Finally, mixing the TNF with polymyxin B, which has been reported 
to bind and reduce the biologic activity of LPS did not abolish the 
activity of the TNF (II). These results are also summarized in Table I. 
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Figure ]. Kinetics of IV administration of 1.0 pg TNF in CBA/J mice. 
Peripheral blood was collected at the indicated time intervals and a 
differential count performed. A brief relative lymphocytosis and neutro- 
penia was followed by a more pronounced and longer lasting lymphopenia 
and neutrophilia. Each value is mean + SEM for 3 to 14 mice * = p<.05 
compared to normal mice (Time 0). 
The kinetics of the TNF-induced changes are shown in Figure I. Upon 
intravenous infusion of TNF, there was a brief lymphocytosis at 15 and 30 
minutes followed by a dramatic reduction in the percent of circulating 
lymphocytes at 1 hour. This decrease in the per cent of circulating 
lymphocytes persisted up to the 6 hour point where there was still a 30% 
reduction. The change in the circulating lymphocytes was mirrored by 
alterations in the peripheral PMN population. There was a sharp reduc- 
tion in the per cent of circulating PMNs at 15 and 30 minutes followed by 
an increase at 1 hour. As with the lymphopenia, the neutrophilia per- 
sisted throughout the 6 hour study period. These relative changes in 
lymphocytes and PMNs were matched by absolute changes in the cell num- 
bers. The kinetics of the absolute numbers of lymphocytes and PMNs 
post-TNF challenge are shown in Figure 2. Lymphocyte numbers demonstrat- 
ed a gradual, but steady, decline reaching a nadir at 2-4 hours post-TNF 
injection. PMN numbers appeared to increase in a step-wise fashion, 
reaching the first plateau at 1-2 hours post-challenge and a second 
plateau at the 4-6 hour mark. To further elucidate the composition of 
the neutrophilia, we enumerated the immature neutrophils, since the 
peripheral neutrophilia may have been due to entry of marginated PMNs or 
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Figure 2. Kinetics of total cells following IV administration of 1.0 ~g 
TNF. At the indicated time points the blood was collected and a white 
count done. A brief absolute neutrophilia was followed by a more pro- 
nounced and longer lasting neutrophilia, while the lymphopenia became 
evident even at the earliest time point (15 minutes). Each value is mean 
± SEM for 3 to 14 mice * = p<.05 compared to normal mice (Time 0). 
the recruitment of immature cells from the bone marrow. Immature PMNs 
were identified morphologically as peripheral blood neutrophils with 
ringed nuclei (I0). As shown in Figure 3, the augmentation in the 
circulating PMN population in response to TNF challenge was primarily due 
to recruited immature neutrophils, although the number of mature cells 
was also significantly increased over control values at 4 and 6 hours 
post-challenge. The recruitment of immature PENs occurred earlier, as 
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Figure 3. Kinetics of immature neutrophils. A differential count of 
peripheral blood smears showed increasing numbers of immature neutro- 
phils. The neutrophilia was due to both mature and immature forms. Each 
value is mean ± SEM for 3 to 14 mice * = p<.05 compared to normal mice 
(Time 0). 
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Discussion 
The above study demonstrates that human recombinant tumor necrosis 
factor (TNF) administered intravenously in CBA/J mice induces profound 
alterations in the peripheral blood leukocytes. These changes consisted 
of an early mild lymphocytosis followed by a dramatic lymphopenia, and a 
parallel neutropenia followed by neutrophilia. These changes were found 
to be both relative and absolute. The neutrophilia was due predominantly 
to immature cells. Control studies demonstrated that potential LPS 
contamination was not contributing to our results. 
It has been postulated that many of the biologic effects of LPS are 
mediated through TNF; that is LPS induces TNF secretion by mononuclear 
phagocytes and the latter mediator causes the in vivo alterations. 
Evidence for this hypothesis is provided by studies that show a rapid 
rise in TNF titers in the peripheral blood levels of infected mice 
challenged with LPS (12). Further support is found in Beutler's work 
where antibodies directed against murine TNF was able to prolong survival 
in mice challenged with a lethal dose of LPS (5). It is also interesting 
to note that the TNF-induced peripheral blood alterations that we ob- 
served in our investigation are very similar to those induced in humans 
(6-8) and calves (9) following intravenous infusion of LPS. In these 
previous studies, an early neutropenia was followed by a marked neutro- 
philia, due primarily to immature PMNs, while the lymphocyte populations 
were reduced following LPS challenge. Since we are able to induce 
similar changes by administering TNF these studies also suggest that the 
LPS may be acting through release of TNF. Further studies are underway 
to elucidate the mechanism of TNF's effect on the lymphocytes. 
Several questions are raised by this study. Although the lympho- 
cytes are reduced in both number and per cent, the effects of TNF on 
specific lymphocyte populations is not clear. It is not known if partic- 
ular subsets were diminished or if there was an effect on all lymphocyte 
populations. Previous work demonstrated that TNF was cytotoxic to normal 
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murine B cells (13); thus, the reduction of lymphocytes in the peripher- 
al blood may have been through a direct cytotoxic action. Studies are 
underway to characterize the phenotypes of the peripheral blood lympho- 
cytes to ascertain if the B cells are preferential targets. In addition, 
TNF may cause changes by altering the vascular endothelium. This is 
especially intriguing since Pohlman (14) and Pober (15) have demonstrated 
an up-regulation of a specific endothelial cell surface protein by TNF 
that may be involved in leukocyte adherence. 
These studies further support the hypothesis that TNF may serve as 
an important peptide mediator with regard to in vivo LPS-induced 
alterations. 
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